Raymond James & Associates Acquires 27,158 Shares of Repligen Co. (NASDAQ:RGEN)

Raymond James & Associates boosted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 49.3% in the third quarter, Holdings Channel reports. The firm owned 82,277 shares of the biotechnology company’s stock after purchasing an additional 27,158 shares during the quarter. Raymond James & Associates’ holdings in Repligen were worth $12,244,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of RGEN. Norden Group LLC boosted its holdings in shares of Repligen by 1,711.6% in the 1st quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after acquiring an additional 36,663 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Repligen by 30.2% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock valued at $5,312,000 after acquiring an additional 6,705 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Repligen by 21.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 335,836 shares of the biotechnology company’s stock worth $61,767,000 after purchasing an additional 59,903 shares during the last quarter. Swedbank AB acquired a new stake in shares of Repligen in the 1st quarter valued at $5,518,000. Finally, Banque Pictet & Cie SA boosted its holdings in Repligen by 74.6% in the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock valued at $4,351,000 after acquiring an additional 14,746 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on RGEN shares. Benchmark reaffirmed a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. UBS Group cut their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Finally, Stephens reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Insider Buying and Selling at Repligen

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Repligen Stock Up 0.2 %

Shares of RGEN opened at $135.45 on Monday. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The firm’s 50 day moving average is $143.45 and its 200-day moving average is $147.04. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.57 billion, a PE ratio of 541.80, a P/E/G ratio of 4.16 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company’s revenue was down 3.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.53 earnings per share. Equities research analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.